Acrivon Therapeutics, Inc. Common Stock (ACRV)
USD 6.69
(-7.21%)
USD 6.69
(-7.21%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Cost of Revenue | 536 Thousand | 1.09 Million | 832 Thousand | 13 Thousand |
| Gross Profit | -536 Thousand | -1.09 Million | -832 Thousand | -13 Thousand |
| Operating Expenses | 66.7 Million | 32.65 Million | 16.18 Million | 3.16 Million |
| Selling, General and Administrative Expenses | 21.21 Million | 8.7 Million | 2.46 Million | 1.29 Million |
| Research and Development Expenses | 45.48 Million | 23.94 Million | 13.71 Million | 1.87 Million |
| Other Expenses | - | 1.49 Million | -59 Thousand | -2.13 Million |
| Cost and Expenses | 67.23 Million | 32.65 Million | 16.18 Million | 3.16 Million |
| Operating Income | -67.23 Million | -32.65 Million | -16.18 Million | -3.16 Million |
| Interest Expense | - | - | - | - |
| Income Tax Expense | - | -1.49 Million | -199.55 Thousand | -193.29 Thousand |
| Earnings before Tax | -60.38 Million | -31.16 Million | -16.24 Million | -5.3 Million |
| Net Income | -60.38 Million | -29.67 Million | -16.24 Million | -5.3 Million |
| Earnings Per Share Basic | -2.74 | -1.35 | -0.78 | -0.25 |
| Earnings Per Share Diluted | -2.74 | -1.35 | -0.78 | -0.25 |
| Weighted Average Shares Outstanding | 22.07 Million | 21.92 Million | 20.85 Million | 20.85 Million |
| Weighted Average Shares Outstanding (Diluted) | 22.07 Million | 21.92 Million | 20.85 Million | 20.85 Million |
| Gross Margin | - | - | - | - |
| EBIT Margin | - | - | - | - |
| Profit Margin | - | - | - | - |
| EBITDA | -59.85 Million | -30.07 Million | -15.41 Million | -5.29 Million |
| Earnings Before Tax Margin | - | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 1.88 Million | - | - | - |
| Cost of Revenue | 200 Thousand | 224 Thousand | 149 Thousand | 536 Thousand | 331 Thousand | 295 Thousand |
| Gross Profit | -200 Thousand | -224 Thousand | 1.73 Million | -536 Thousand | -331 Thousand | -295 Thousand |
| Operating Expenses | 21.23 Million | 17.44 Million | 20.9 Million | 66.7 Million | 16.13 Million | 15.52 Million |
| Selling, General and Administrative Expenses | 6.41 Million | 6.19 Million | 5.57 Million | - | 5.87 Million | 4.99 Million |
| Research and Development Expenses | 14.82 Million | 11.24 Million | 15.32 Million | - | 10.26 Million | 10.52 Million |
| Other Expenses | -55 Thousand | -264 Thousand | 1.8 Million | - | 1.67 Million | 1.6 Million |
| Cost and Expenses | 21.43 Million | 17.66 Million | 21.05 Million | 67.23 Million | 16.13 Million | 15.52 Million |
| Operating Income | -21.43 Million | -17.66 Million | -21.05 Million | -67.23 Million | -16.13 Million | -15.52 Million |
| Interest Expense | - | - | 1.63 Million | - | - | - |
| Income Tax Expense | - | 180.72 Thousand | 1.77 Million | 1.00 | -133 Thousand | 6915.00 |
| Earnings before Tax | -18.79 Million | -16.48 Million | -19.25 Million | -60.38 Million | -14.46 Million | -13.91 Million |
| Net Income | -18.79 Million | -16.48 Million | -19.25 Million | -60.38 Million | -14.46 Million | -13.91 Million |
| Earnings Per Share Basic | -0.52 | -0.73 | -0.86 | - | -0.66 | -0.63 |
| Earnings Per Share Diluted | -0.52 | -0.73 | -0.86 | - | -0.66 | -0.63 |
| Weighted Average Shares Outstanding | 36.13 Million | 22.59 Million | 22.33 Million | 22.07 Million | 22.08 Million | 21.97 Million |
| Weighted Average Shares Outstanding (Diluted) | 36.13 Million | 22.59 Million | 22.33 Million | 22.07 Million | 22.08 Million | 21.97 Million |
| Gross Margin | - | - | 0.92 | - | - | - |
| EBIT Margin | - | - | -11.10 | - | - | - |
| Profit Margin | - | - | -10.22 | - | - | - |
| EBITDA | -21.23 Million | -17.44 Million | -20.9 Million | - | -16.13 Million | -15.39 Million |
| Earnings Before Tax Margin | - | - | -11.17 | - | - | - |
300108
SMID
000881
6130
AGGG
CLB